Form 4: DiaMedica Therapeutics Director Richard D. Pilnik Reports Stock Option Grant
SEC Form 4 Filing
Director Richard D. Pilnik reports acquisition of stock options and updates to beneficial ownership of DiaMedica Therapeutics Inc. shares.
Summary
- On June 1, 2024, Richard D. Pilnik, a director of DiaMedica Therapeutics Inc., reported transactions related to the company's stock.
- Pilnik acquired 36,065 stock options with an exercise price of $2.90, vesting in quarterly installments over one year and expiring on May 31, 2034.
- Pilnik's total direct holdings include 278,602 voting common shares, inclusive of shares issuable upon settlement of deferred share units.
- The report was filed on June 3, 2024, by Amy Culbert, attorney-in-fact.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing, so the sentiment is neutral. It reflects insider transactions, which can be interpreted in various ways but doesn't inherently indicate positive or negative sentiment.
Positives
- The acquisition of stock options by a director could be seen as a positive sign, indicating confidence in the company's future performance.
Industry Context
This filing is a routine disclosure required by the SEC for corporate insiders and provides transparency regarding their holdings and transactions in the company's stock.
Key Dates
| Date | Description |
|---|---|
| 06/01/2024 | Date of earliest transaction (stock option grant) |
| 06/01/2024 | Date of stock option grant |
| 05/31/2034 | Expiration date of stock options |
| 06/03/2024 | Date of Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.